Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs
  • M&A / Deals

LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs

Pharmaceutical Business Review

Executives from both organisations, including LG AI Research head Woohyung Lim and D D Pharmatech CEO Seulki Lee, attended the event to formalise the partnership.

Read full story

pharminent June 18, 2026 (Last updated: June 19, 2026)

Pharmaceutical Business Review

Executives from both organisations, including LG AI Research head Woohyung Lim and D D Pharmatech CEO Seulki Lee, attended the event to formalise the partnership.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Biogen pens $1bn deal to buy immunology biotech RayThera
Next: GSK claims FDA okay for first oral carbapenem antibiotic

Related Stories

  • M&A / Deals

J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout

pharminent July 31, 2026
  • M&A / Deals

Eisai and CORE Biomedicine agree on global licence for oncology pipeline

pharminent July 29, 2026
  • M&A / Deals

Argenx signs agreement to buy Forte Biosciences for $2.2bn

pharminent July 28, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.